Clinical trial
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic…
NCT00103428 · Cell Genesys, Industry · Terminated
Key facts
| NCT number | NCT00103428 |
|---|---|
| Title | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Official title | A Phase 1/2a Dose-Escalation Trial of Intravenous CG7870 in Combination With Docetaxel in Chemotherapy-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Lead sponsor | Cell Genesys, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | CG7870 |
| Enrollment | 69 |
| Start date | Aug 1, 2004 |
| First posted | Feb 9, 2005 |
| Last update posted | Feb 2, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: